| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Mar 15, 2019 | Beware the hype over the Apple Watch heart app. The device could do more harm than good | Set your smartwatch alarm. You’re about to be barraged by tons of hype about the health benefits of the Apple Watch. Unfortunately, it won’t include essential information and data that can put these claims in proper perspective.
Last year, ... |
| May 25, 2017 | New cardio target ANGPTL3 with promising new studies; Liverpool says Redx is delinquent; Aslan's $33M Taipei IPO | → Regeneron and Ionis each have publications in The New England Journal of Medicine aimed at a brand new cardio target ANGPTL3. The New York Times chronicles the story, which begins in 1994 when a woman in St. Louis gave a ... |
| Sep 9, 2016 | Pharmalot, Pharmalittle: Pfizer CEO says Clinton drug pricing plan is ‘very negative’ | And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is very modest. We hope to catch up on our naps and our reading, a... |
| Jun 22, 2016 | Pharmalot, Pharmalittle: India revising laws to upgrade drug safety | Hello, folks, and how are you today? ’Tis the middle of the week, which calls for a celebratory cup of stimulation. After all, you made it this far, so why not forge ahead? Besides, a warm, shiny sun is enveloping the Pharmalot campus, whic... |
| Jun 10, 2016 | Pharmalot, Pharmalittle: Are too many companies chasing the same kind of cancer drug? | And so, another working week will soon draw to a close. Not a moment, too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather busy. We hope to escort Mrs. Pharmalot to a rent party,... |
| May 19, 2016 | Why a drug that lowers cholesterol doesn’t save lives | This is one of our periodic Five Year Watch columns, examining whether and why predictions of scientific progress were accurate, or hype.
Five years ago, a new class of cholesterol-lowering drugs was drawing lots of praise, even being calle... |
| Mar 9, 2016 | Pharmalot, Pharmalittle: Proposal to lower Medicare drug costs prompts anger | Rise and shine, everyone, and welcome to the middle of the week. This marks a small milestone of sorts, and you deserve congratulations for making it this far. So why not continues, yes? Then again, consider the alternatives. With that in m... |
| Feb 3, 2016 | All wet: Novartis is slammed for ‘alarmist’ ad for heart failure drug | Novartis may have just handed the many critics of pharmaceutical advertising a gift.
The drug maker is running a promotional campaign, including a 30-second TV spot, designed to raise awareness of heart failure. But the campaign, which feat... |
| Dec 21, 2015 | Pharmalot, Pharmalittle: US prices higher for top-selling drugs, FDA investigating Theranos | Good morning, everyone, and welcome to another working week. Although this will be an abbreviated stretch due to the impending holiday. Nonetheless, we are as busy as ever. After all, the world continues to spin. This calls for a cup or mor... |
| Oct 2, 2014 | Analyst: Edwards Lifesciences’ Sapien 3 poised to lead TAVI market | MassDevice.com On Call | MASSDEVICE ON CALL — Edwards Lifesciences (NYSE:EW) is poised to take the lead in the transcatheter aortic valve market with its Sapient 3 replacement heart valve, according to Leerink Partners analyst Danielle Antalffy.
Writing yesterday i... |
| Sep 3, 2014 | Bluegrass Vascular taps ex-ArthoCare R&D chief Niederauer for CEO | Personnel Moves | Bluegrass Vascular Technologies said it named Gabriele Niederauer its new president & CEO, hard on the heels of a Series A funding round that brought in $4.5 million for its Surfacer central venous catheter.
Niederauer, the former vice ... |
| Mar 28, 2013 | Will another Durata failure report drag St. Jude down? | Wall Street didn’t move much on news of another insulation-related failure in St. Jude Medical’s (NYSE:STJ) next-generation Durata defibrillator leads this week.
The case report included a detailed analysis of an incident in which a Durata ... |
| Jan 23, 2013 | Seven survival strategies for doctors in the new world of healthcare reform | Tips for survival in the new healthcare environment
By Dr. Jay Schloss
1. Good Tech: It’s time to admit much of your job is now data entry. If that’s the case, you should arm yourself with the best technology to make this job palatable. For... |
| Aug 13, 2012 | High-voltage Riata ST defibrillator lead failure and its implications for Durata | By Westby G. Fisher, MD, FACC
It came from a case report published online before print in PACE from Dr. John Marenco of Tufts University in Springfield, Massachusetts:
A 60-year-old man had a single-chamber St.Jude Atlas VR defibrillator (S... |
| May 17, 2012 | Durata: Questioning the 99% | By Westby G. Fisher, MD, FACC
One of Many St. Jude Ad Trucks Seen at HRS 2012 Scientific Sessions
The boxing match about the safety of St. Jude Medical’s newer Durata defibrillator lead reliability continues to spark interest in the EP comm... |
| May 14, 2012 | HRS 2012 Roundup: Cameron Health, Topera Medical and Riata take center stage | More than 35,000 physicians, allied healthcare providers and industry representatives descended on the cavernous convention center in Boston’s up-and-coming Seaport section for the Heart Rhythm Society’s annual meeting.
And although the top... |
| Apr 13, 2012 | St. Jude Medical gets tangled in its own rope over Riata | The medical device world was abuzz this week as St. Jude Medical (NYSE:STJ) came out swinging against critics of its recalled Riata defibrillator lead.
The St. Paul, Minn.-based company’s vociferous response reportedly has doctors and inves... |
| Feb 16, 2012 | The Riata ICD lead recall: Two perspectives | By Westby G. Fisher, MD, FACC
Robert Hauser, MD published a perspective piece in the New England Journal of Medicine today entitled "Here We Go Again — Another Failure of Postmarketing Device Surveillance." In the piece, he offers... |
| Feb 6, 2012 | Doctors helping doctors (and their patients) via social media | By Westby G. Fisher, MD, FACC
It was supposed to be a closed meeting attended by doctors who had a large amount of experience dealing with patients with St. Jude Riata leads, a defibrillator lead that recently garnered an FDA Class I adviso... |
| Feb 6, 2012 | Medicare proposes TAVI reimbursement guidelines | Updated 12:10 p.m. with comments from Edwards Lifesciences.
Clockwise from top left: Medtronic’s CoreValve, Edwards Lifesciences’ Sapien, St. Jude Medical’s Portico
The Centers for Medicare & Medicaid Services released a proposal detail... |
| Jan 29, 2012 | Speaking doctor-to-doctor(s) using healthcare social media | 20 Jan Edward J Schloss MD @EJSMD
At Riata ICD Lead Summit in Minneapolis.
20 Jan Edward J Schloss MD @EJSMD
35% of #StJude #Riata Summit attendees think this is a worse problem than MDT Fidelis.
20 Jan Edward J Schloss MD @EJSMD
41% of #St... |
| Jan 23, 2012 | UPDATE: St. Jude responds to Riata summit | Analysts warned against reading too much into poll results from a 1-day conference of cardiovascular leaders, in which more than half said the ongoing recall of St. Jude Medical’s (NYSE:STJ) Riata defibrillator leads is a more serious issue... |
| Jan 2, 2012 | Teva Pharmaceuticals’ new CEO is Jeremy Levin (Morning Read) | “Investors will like the idea that Shlomo’s replacement is from the industry and someone with knowledge and experience, especially from the innovative side of the business,” Natali Gotlieb, an analyst for Israel Brokerage & Investments ... |
| Dec 12, 2011 | As goes the post office, so too Medicare? | By Westby G. Fisher, MD, FACC
With the announcement that the Center for Medicare and Medicaid Services (CMS) will begin auditing 100% of expensive cardiovascular and orthopedic procedures in certain states earlier this week, we see their fi... |
| Jan 24, 2011 | The limits of the DOJ’s defibrillator investigation | By Westby G. Fisher, MD, FACC
From the Heart Rhythm Society member’s website today:
“The Heart Rhythm Society (HRS) is aware of an ongoing U.S. Department of Justice (DOJ) civil investigation of Implantable Cardioverter Defibrillator (ICD) ... |
| Seven survival strategies for doctors in the new world of healthcare reform | It is with great pleasure that I offer the following guest post from Edward J. Schloss, MD, (Twitter ID @EJSMD) the medical director of cardiac electrophysiology at Christ Hospital in Cincinnati, OH.
One of the many rewards of writing a blo... |
| Speaking doctor-to-doctor(s) using healthcare social media | It was supposed to be a closed meeting attended by doctors who had a large amount of experience dealing with patients with St. Jude Medical’s Riata leads, a defibrillator lead that recently garnered an FDA Class I advisory (recall) status d... |
| Teva Pharmaceuticals’ new CEO is Jeremy Levin (Morning Read) | Current medical news and unique business news for anyone who cares about healthcare.
Meet Teva’s Jeremy Levin. The former Bristol-Meyers Squibb and Novartis executive will take over the company in May 2012 when Shlomo Yanai retires. The swi... |
